Finance

Beta
Lists
SYRE:NASDAQ
Spyre Therapeutics Inc
$88.67
0.00%
(0.00) 1D
Jun 25, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SYRE...
Mkt. cap
7.70B
Avg. vol.
1.35M
Volume
919.00
52-wk high
$102.06
52-wk low
$14.00
EPS
-$2.50
Beta
3.05
Shares outstanding
86.84M
No. of employees
112
Mkt. cap
7.70B
Avg. vol.
1.35M
Volume
919.00
52-wk high
$102.06
52-wk low
$14.00
EPS
-$2.50
Beta
3.05
Shares outstanding
86.84M
No. of employees
112
News stories
From sources across the web
About Spyre Therapeutics Inc
CEO-
Employees112
FoundedJan 1, 2013
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitespyre.com
Analyst ratings
Based on 16 analysts giving stock ratings to SYRE in the past 3 months
Strong buy
Buy
16
Hold
0
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for SYRE in the last 3 months.
Highest
Current $88.67
$135.00 (+52.25%)
Average
$101.50 (+14.47%)
Lowest
$80.00 (-9.78%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Hoang
Deutsche Bank
Buy
Maintained
$135.00
+52.2%
06/23/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
06/23/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Reiterated
$107.00
+20.7%
06/22/2026
David Nierengarten
Wedbush
Buy
Maintained
$100.00
+12.8%
06/16/2026
Akash Tewari
Jefferies
Buy
Maintained
$98.00
+10.5%
06/16/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$103.00
+16.2%
06/15/2026
Julian Harrison
BTIG
Buy
Maintained
$112.00
+26.3%
06/15/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$104.00
+17.3%
06/16/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
06/03/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$115.00
+29.7%
05/06/2026
Samantha Semenkow
Citi
Buy
Reiterated
$97.00
+9.4%
05/06/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$84.00
-5.3%
04/14/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$90.00
+1.5%
04/14/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
$90.00
+1.5%
04/14/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$106.00
+19.5%
04/13/2026
Martin Auster
Raymond James
Buy
Initiated
$80.00
-9.8%
04/10/2026
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.74 / -$0.65
-13.11%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
40.14M
45.25M
44.64M
-
Cost of revenue
40.14M
45.25M
44.64M
-
Research and development expenses
-
-
-
60.41M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.79M
11.64M
12.53M
15.23M
Operating expense
11.79M
11.64M
12.53M
75.64M
Total operating expenses
51.94M
56.89M
57.17M
75.64M
Operating income
-51.94M
-56.89M
-57.17M
-75.64M
Other non operating income
-656.00K
40.33M
-12.50M
-30.36M
EBT including unusual items
-36.72M
-11.18M
-62.53M
-69.00M
EBT excluding unusual items
-46.72M
-11.18M
-62.53M
-99.00M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36.72M
-11.18M
-62.53M
-69.00M
Net profit margin
-
-
-
-
Earnings per share
-0.49
-0.15
-0.74
-0.74
Interest and investment income
5.87M
5.38M
7.14M
7.00M
Interest expense
-
-
-
-
Net interest expenses
5.87M
5.38M
7.14M
7.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-10.00M
-
-
-30.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of SYRE
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer